Your shopping cart is currently empty

N-Oleoyl glycine, a lipoamino acid, was able to promote 3T3-L1 adipogenesis through the activation of CB1 receptor and the enhancement of insulin-mediated Akt signaling pathway.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $39 | In Stock | In Stock | |
| 10 mg | $64 | In Stock | In Stock | |
| 25 mg | $98 | In Stock | - | |
| 50 mg | $153 | In Stock | - | |
| 100 mg | $229 | In Stock | - | |
| 200 mg | $342 | Inquiry | Inquiry | |
| 1 mL x 10 mM (in DMSO) | $60 | In Stock | In Stock |
| Description | N-Oleoyl glycine, a lipoamino acid, was able to promote 3T3-L1 adipogenesis through the activation of CB1 receptor and the enhancement of insulin-mediated Akt signaling pathway. |
| In vitro | N-Oleoyl glycine stimulated lipid accumulation and significantly increased adipogenic genes (PPARγ and aP2), in a dose- and time-dependent manner.?Additionally, N-Oleoyl glycine markedly increased the mRNA expression of CB1 receptor and the inhibition of CB1R by its antagonist SR141716 abolished the promotive effects of N-Oleoyl glycine on lipid accumulation and the protein expression of PPARγ and aP2.?Furthermore, N-Oleoyl glycine increased the ratio of p-Akt/Akt and p-FoxO1/FoxO1, which could be reversed by SR141716.?Moreover, N-Oleoyl glycine-induced enhancement of adipogenesis, activation of insulin-mediated Akt signaling pathway and inactivation of FoxO1 were effectively blocked by Wortmannin, a specific PI3K/Akt inhibitor, indicating the essential role of Akt signaling pathway in the process of N-Oleoyl glycine-stimulated 3T3-L1 adipogenesis[1]. |
| Molecular Weight | 339.51 |
| Formula | C20H37NO3 |
| Cas No. | 2601-90-3 |
| Smiles | CCCCCCCC\C=C/CCCCCCCC(=O)NCC(O)=O |
| Relative Density. | 0.962g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (235.63 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 3.3 mg/mL (9.72 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.